BR112014004065A2 - micro-organismos carregando um antígeno de tumor - Google Patents

micro-organismos carregando um antígeno de tumor

Info

Publication number
BR112014004065A2
BR112014004065A2 BR112014004065A BR112014004065A BR112014004065A2 BR 112014004065 A2 BR112014004065 A2 BR 112014004065A2 BR 112014004065 A BR112014004065 A BR 112014004065A BR 112014004065 A BR112014004065 A BR 112014004065A BR 112014004065 A2 BR112014004065 A2 BR 112014004065A2
Authority
BR
Brazil
Prior art keywords
microorganisms
core
tumor antigen
microorganisms carrying
carrying
Prior art date
Application number
BR112014004065A
Other languages
English (en)
Portuguese (pt)
Inventor
Toutounian Kawe
Ulsemer Philippe
Goletz Steffen
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of BR112014004065A2 publication Critical patent/BR112014004065A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1257—Gram-negative bacteria from Bacteridaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112014004065A 2011-08-22 2012-08-22 micro-organismos carregando um antígeno de tumor BR112014004065A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526054P 2011-08-22 2011-08-22
EP11178322 2011-08-22
PCT/EP2012/066360 WO2013026887A1 (en) 2011-08-22 2012-08-22 Microorganisms carrying a tumor antigen

Publications (1)

Publication Number Publication Date
BR112014004065A2 true BR112014004065A2 (pt) 2017-03-14

Family

ID=47745974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004065A BR112014004065A2 (pt) 2011-08-22 2012-08-22 micro-organismos carregando um antígeno de tumor

Country Status (11)

Country Link
US (1) US9700610B2 (https=)
EP (1) EP2748302B1 (https=)
JP (1) JP6148671B2 (https=)
CN (1) CN103814123A (https=)
AU (1) AU2012298496A1 (https=)
BR (1) BR112014004065A2 (https=)
CA (1) CA2844543A1 (https=)
ES (1) ES2686313T3 (https=)
IL (1) IL231065A0 (https=)
RU (1) RU2014110953A (https=)
WO (1) WO2013026887A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
EP3090749B1 (en) * 2013-12-20 2023-08-30 Daicel Corporation Nutrient composition having lipid metabolism-improving action
CN116410324A (zh) * 2023-05-24 2023-07-11 西安交通大学医学院第一附属医院 一种肠道微生物脆弱拟杆菌毒素中和纳米抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
ATE241011T1 (de) 1991-02-27 2003-06-15 Micromet Ag Serin-reiche peptidlinker
EP0636029B1 (en) 1992-04-13 2000-11-08 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
DE69815707T2 (de) 1997-11-20 2004-07-01 Vical, Inc., San Diego Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
WO2000052135A2 (en) 1999-03-02 2000-09-08 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr) 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US7510735B2 (en) 2001-02-01 2009-03-31 Kabushiki Kaisha Yakult Honsha Method of evaluating the extent of reaching the intestine of bifidobacterium in fermented milk food or drink
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20050042714A1 (en) 2001-08-17 2005-02-24 Michael Pawlita Glycoconjugates of sialic acid derivates, methods for their production and use thereof
US20040115177A1 (en) 2001-10-12 2004-06-17 Harris Delbert L. Probiotic compositions and methods against bacterial infection in livestock animals
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
WO2003044051A1 (en) 2001-11-20 2003-05-30 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
US8887358B2 (en) * 2003-02-14 2014-11-18 Christie Marie Cox Burial vault carapace and method for customizing a burial vault carapace
GB0315991D0 (en) 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2425475T3 (es) 2003-08-18 2013-10-15 Glycotope Gmbh Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
WO2005108423A1 (en) 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
EP1789027B1 (en) 2004-07-26 2013-09-04 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
US7598134B2 (en) 2004-07-28 2009-10-06 Micron Technology, Inc. Memory device forming methods
WO2007041495A2 (en) * 2005-09-29 2007-04-12 University Of California, San Diego Dampening humoral and innate immunity by inhibition of ppgalnact-1
EP2013357A4 (en) * 2006-04-19 2012-02-22 Biogenerix Ag EXPRESSION OF O-GLYCOSYLATED THERAPEUTIC PROTEINS IN PROKARYOTIC MICROORGANISMS
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
SI2073842T1 (sl) 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
AR063868A1 (es) * 2007-11-20 2009-02-25 Tecn Conicet Consejo Nac De In Inmunogeno modificado del disacarido de thomsen- friedenreich (tfd) procedimiento de elaboracion, composiciones que lo contine, usos y metodos de tratamiento
US20090324617A1 (en) * 2008-01-24 2009-12-31 Glykos Finland Ltd. Cancer specific glycans and use thereof
AR071787A1 (es) * 2008-05-13 2010-07-14 Glycotope Gmbh Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento
US8784293B2 (en) 2008-10-07 2014-07-22 Advanced Brain Monitoring, Inc. Systems and methods for optimization of sleep and post-sleep performance
CN101560488A (zh) 2009-05-27 2009-10-21 中国农业大学 分解木质纤维素的酶与菌剂
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US20110076356A1 (en) * 2009-09-29 2011-03-31 Ziemer Cherie J Novel Fibro-Biotic Bacterium Isolate
GB2475226A (en) * 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
WO2012112716A1 (en) * 2011-02-16 2012-08-23 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
US8951762B2 (en) * 2011-07-27 2015-02-10 Iowa State University Research Foundation, Inc. Materials and methods for using an acyl—acyl carrier protein thioesterase and mutants and chimeras thereof in fatty acid synthesis
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
US9234204B2 (en) * 2012-08-07 2016-01-12 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9518872B2 (en) 2014-10-14 2016-12-13 Kidde Technologies, Inc. Thermal sensor

Also Published As

Publication number Publication date
CN103814123A (zh) 2014-05-21
JP2014529403A (ja) 2014-11-13
ES2686313T3 (es) 2018-10-17
EP2748302B1 (en) 2018-08-15
CA2844543A1 (en) 2013-02-28
US20140302093A1 (en) 2014-10-09
IL231065A0 (en) 2014-03-31
US9700610B2 (en) 2017-07-11
WO2013026887A1 (en) 2013-02-28
JP6148671B2 (ja) 2017-06-14
AU2012298496A1 (en) 2014-02-27
RU2014110953A (ru) 2015-09-27
EP2748302A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014026703A2 (pt) inibidores de dna-pk
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BR112015014372A2 (pt) inibidores de autotaxina
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112012032028A2 (pt) compostos de tioacetato, composições e métodos de uso.
UA113712C2 (xx) Антитіло до fap і способи його застосування
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
MX366925B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
BR112014009790A2 (pt) composto para modulação antisense da expressão de gccr, seu uso e composição
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112012009432A2 (pt) anticorpo anti-hsv
BR112014006587A2 (pt) modulação antisense da expressão de gcgr
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
BR112015019412A2 (pt) inibidores de bace1
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.